Fundraising Fox

Alzheon

Framingham, US · Founded 2013 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

MT
Martin Tolar, M.D., Ph.D.President and Chief Executive Officer
GE
Glenn E. PaulyChief Commercial Officer
SA
Susan Abushakra, M.D.Chief Medical Officer
JH
John Hey, Ph.D.Chief Scientific Officer
KA
Kenneth A. MaceTreasurer and Chief Financial Officer
AA
Adem AlbayrakChief Data Officer
DN
David NikodemDirector
FB
Franklin BergerDirector
MT
Martin TolarExecutive Officer, Director
MB
Menghis BairuDirector
MA
Michael AcetiExecutive Officer
FH
Franz HeftiDirector

Investors · 1

ARCH Venture PartnersreportedChicago · $50K – $250Mvia Scott Minick · board

Reported raises · per SEC filings

Form D private placements
▶$126.3MraisedFeb 2025 · 76 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Diane K. Jorkasky, M.D.Director
  • Muneer SatterDirector
  • Neil W. FlanzraichDirector
  • Glenn E. PaulyExecutive Officer
  • Susan Abushakra, M.D.Executive Officer
  • John Hey, Ph.D.Executive Officer
  • Kenneth A. MaceExecutive Officer
  • Martin Tolar, M.D., Ph.D.Executive Officer, Director
  • Gino SantiniDirector
  • Christopher Noel DunnDirector
  • Adem AlbayrakExecutive Officer
  • Jordan HellerDirector
  • Aidan Power, MRCPsychExecutive Officer
Offering amount
$150M
Amount sold
$126.3M
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$1.7MraisedJan 2023 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John Hey, Ph.D.Executive Officer
  • Aidan Power, MRCPsychExecutive Officer
  • Diane K. Jorkasky, M.D.Director
  • Kenneth A. MaceExecutive Officer
  • Susan Abushakra, M.D.Executive Officer
  • Christopher Noel DunnDirector
  • Jordan HellerDirector
  • Martin Tolar, M.D., Ph.D.Director, Executive Officer
  • Neil W. FlanzraichDirector
Offering amount
$50M
Amount sold
$1.7M
First sale
Dec 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedSep 2020 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Diane K. Jorkasky, M.D.Director
  • Kenneth A. MaceExecutive Officer
  • Martin Tolar, M.D., Ph.D.Director, Executive Officer
  • Susan Abushakra, M.D.Executive Officer
  • Noel DunnDirector
  • John Hey, Ph.D.Executive Officer
  • Jordan HellerDirector
  • Neil W. FlanzraichDirector
Offering amount
$50M
Amount sold
$2.4M
First sale
Sep 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.2MraisedJan 2020 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jordan HellerDirector
  • Kenneth A. MaceExecutive Officer
  • Neil W. FlanzraichDirector
  • Diane K. Jorkasky, M.D.Director
  • Noel DunnDirector
  • David Nikodem, Ph.D.Director
  • Martin Tolar, M.D., Ph.D.Director, Executive Officer
Offering amount
$6.2M
Amount sold
$6.2M
First sale
Apr 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$19.8MraisedSep 2018 · 81 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jean-Pierre GarnierDirector
  • Scott MinickDirector
  • Dennis LangerDirector
  • Martin TolarExecutive Officer, Director
  • Kenneth A. MaceExecutive Officer
  • Neil W. FlanzraichDirector
  • Franz HeftiDirector
  • David NikodemDirector
Offering amount
$19.8M
Amount sold
$19.8M
Sales commissions
$190K
Placement agents
CIM Securities, LLC
First sale
May 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedFeb 2016 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ken MaceExecutive Officer
  • David NikodemDirector
  • Jean-Pierre GarnierDirector
  • Dennis LangerDirector
  • Scott MinickDirector
  • Martin TolarExecutive Officer, Director
  • Franz HeftiDirector
Offering amount
$5M
Amount sold
$1.3M
Sales commissions
$78K
Placement agents
CIM Securities, LLC
First sale
Feb 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.9MraisedJul 2015 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Menghis BairuDirector
  • Michael AcetiExecutive Officer
  • Jean-Pierre SommadossiDirector
  • Franklin BergerDirector
  • Robert SilvermanExecutive Officer
  • David NikodemDirector
  • Franz HeftiDirector
  • John HeyExecutive Officer
  • Martin TolarExecutive Officer, Director
  • Scott MinickDirector
Offering amount
$6.9M
Amount sold
$6.9M
Sales commissions
$402.3K
Placement agents
Brookline Group, LLC
First sale
Jul 2015
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.3MraisedFeb 2015 · 60 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David NikodemDirector
  • Franklin BergerDirector
  • Scott MinickDirector
  • Martin TolarExecutive Officer, Director
  • Menghis BairuDirector
  • Michael AcetiExecutive Officer
  • Franz HeftiDirector
  • John HeyExecutive Officer
  • Jean-Pierre SommadossiDirector
Amount sold
$7.3M
Sales commissions
$720K
Placement agents
Brookline Group, LLC
First sale
Dec 2014
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.